Answers are grounded in this paper and cite their sources.
Background Short-term tolerability and safety of drugs for the treatment of attention-deficit/hyperactivity disorder (ADHD) have been demonstrated in several studies; however, less is known about the safety profiles of individual ADHD drugs and potential differences according to sex and age. Therefore, a comprehensive analysis of adverse drug reactions (ADRs) related to ADHD drugs in three independent data sources covering outpatient and inpatient data was performed. Methods For the analysis, spontaneous reports from the European ADR database (EudraVigilance), systematically collected ADRs in clinical routine data from the TDM-Vigil registry and ADR related hospital admissions from the KiDSafe study, were investigated. Overall, n = 1,169 spontaneous reports related to ADHD drugs, n = 502 patients included in TDM-Vigil exposed to ADHD drugs, and n = 22 patients with ADR related hospital admissions due to ADHD drugs in the KiDSafe study were analysed. Stratified analyses regarding patient demographics and individual ADHD drugs were conducted. Results Methylphenidate was, in terms of absolute numbers, the most frequently suspected causative agent in all three data sources. However, ADR incidence rates per 100 person-years were higher for guanfacine (RR = 2.40 [1.40–4.10]), and atomoxetine (RR = 1.87 [1.23–2.85]) compared to extended-release methylphenidate in TDM-Vigil. Across all three data sources, school-aged children were more frequently represented among patients with ADRs than adolescents. Overall, appetite disorders, gastrointestinal symptoms, and weight loss were the ADRs commonly associated with ADHD drugs in EudraVigilance and TDM-Vigil. Cardiovascular ADRs and seizures ranked among the most frequently recorded ADRs associated with hospitalisation in EudraVigilance and KiDSafe. In EudraVigilance, methylphenidate was disproportionately more often associated with hepatocellular damage and hepatitis, atomoxetine and lisdexamfetamine with suicidal behaviour, and guanfacine with hypotension and bradycardia. No obvious differences were observed between females and males. Conclusion The complementary approach of our study strengthens the robustness of our findings as similar results were consistently observed across the three data sources. ADR incidence rates, ADR frequencies and ADR profiles differed between individual ADHD drugs and between children and adolescents; however, due to the small number of cases in subgroup-stratified analyses, our findings should be considered exploratory and require confirmation in larger studies.
No takes yet. Share an insight, caveat, or question.
Dubrall et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: